Jill is a Partner with SR One based on the east coast. Jill originally joined SR One in 2011 and is managing key investments including Arcellx (ACLX), Odyssey, and Avalyn. In addition to investing responsibilities, she devotes significant time to developing SR One’s talented junior investing team.
Jill has a BS in Chemistry from Duke University and an MS in Biochemistry from Johns Hopkins University. Previously, she worked in strategy consulting and biotech corporate development (Dynavax Technologies, NASDAQ DVAX).
At SR One, we are laser focused on generating clinical proof of concept with new medicines that aim to address the most critical needs of patients. By partnering with top entrepreneurs, we work with our portfolio companies to create new paradigms in medicine.